Annamycin liposomal - Moleculin Biotech

Drug Profile

Annamycin liposomal - Moleculin Biotech

Alternative Names: Annamycin liposomal - University of Texas M.D. Anderson Cancer Center; Annamycin-LF; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNA

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Aronex Pharmaceuticals; Callisto Pharmaceuticals; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Discontinued Acute lymphoblastic leukaemia; Breast cancer; Cancer; Chronic myeloid leukaemia

Most Recent Events

  • 26 Sep 2017 US FDA approves IND application for annamycin liposomal in Acute myeloid leukaemia (Second-line therapy or greater)
  • 29 Aug 2017 Moleculin Biotech resubmits IND application to the US FDA for continued clinical development of annamycin liposomal in Acute myeloid leukaemia (Second-line therapy or greater) in USA
  • 22 Aug 2017 Moleculin plans a phase I/II trial for Acute myeloid leukaemia (Second-line therapy or greater) in USA and Poland in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top